2. Viral hepatitis and liver cancer;M Levrero ;Nature review , 2006
Liver cancer as a result of chronic liver injury
Department of Surgery, University of Tsukuba
3.
4. Study overview
Department of Surgery, University of Tsukuba
Snapshot :
Oval cell is considered the stem cell of liver .
This study tries to investigate the proliferation characteristics, and
tumorgenesis of oval cells .
Male Sprague dawley rat was feed with choline deficient diet CDE(to induce
oval cell )>>>hepatic oval cell isolation >>2 years culture :100 passage >>
Flow cytometry –immunoflurence ( Ov6 , BD-2, BD-2, Dlk antibodies
/markers)>>microscopic morphology study>proliferation ability > colony
formation ability study >>>
Xenograft into immunodeficient mouse to observe tumorgenesis .
HepG2 cell line was used as control in this study .
5. Male Sprague dawley rat was feed with choline
deficient diet CDE(to induce oval cell )-6 weeks
hepatic oval cell isolation
2 years culture :100 passages
study
Xenograft into immunodeficient
mouse to observe tumorgenesis .
Department of Surgery, University of Tsukuba
Research flow
12. Department of Surgery, University of Tsukuba
Hepatic oval cell proliferation capability and
chromosomal stability
13. Department of Surgery, University of Tsukuba
Colony formation assessment: anchorage growth assessment
14. Department of Surgery, University of Tsukuba
In vivo :xenograft to immunodeficient mouse
15. Department of Surgery, University of Tsukuba
In summary, serial passages in vitro did not change the
immunophenotype,proliferation capacity, or differentiation
potential of hepatic oval cells and did not cause spontaneous
maltransformation of these cells.
Therefore, hepatic oval cells without
immortalized manipulation not only provide an expandable
cell source for future cell-therapy utilizations but also may
serve as a cell model for understanding the mechanism of
carcinogenesis
This study also suggests that hepatic oval cells did not
experience spontaneous maltransformations into cancer-
initiating cells, suggesting the safety of utilizing hepatic
stem/progenitor cells for exploitation of stem cell
technology.
Summary
Editor's Notes
This diagram shows the pathogenesis of liver cancer : Chronic liver injury such as hepatitis B and C infection and alcohol can result liver hepatitis and cirrhosis and eventually cancer , this is a multistep progressive process lead to genetic alteration resulting dysplastic nodeules (preneoplastic nodules ) which later develop into cancer.
Pathogenesis of human hepatocellular carcinoma (HCC). Chronic hepatitis B and C and associated liver cirrhosis represent major risk factors for HCC development, being implicated in more than 70% of HCC cases worldwide. Additional etiological factors, which often represent co-factors of an underlying HBV- or HCV-related chronic liver disease, include toxins and drugs (e.g., alcohol, aflatoxins, microcystin, anabolic steroids), metabolic liver diseases (e.g., hereditary hemochromatosis, alpha1-antitrypsin deficiency), steatosis, non-alcoholic fatty liver diseases and diabetes. Hepatocarcinogenesis is a multistep process that may last for decades and involves the progressive accumulation of different genetic alterations ultimately leading to malignant transformation. Regardless of the etiological agent, malignant transformation of hepatocytes is believed to occur through a pathway of increased liver cell turnover, induced by chronic liver injury and regeneration, in a context of inflammation and oxidative DNA damage. Dysplastic nodules and macroregenerative nodules are considered as pre-neoplastic lesions. The detailed analysis of HCC development in experimental animals and the comparison of the results with HCC in humans has identified a variety of genomic and molecular alterations in fully developed HCC and to a lesser extent in morphologically defined pre-neoplastic precursor lesions. At least four pathways that regulate either cell proliferation or cell death (i.e., the phospho-retinoblastoma (pRb), p53, transforming growth factor-beta (TGF-beta) and beta-catenin pathways) are affected in HCCs.
Journal of Gastroenterology and Hepatology (2003) , REVIEW Oval cell-mediated liver regeneration: Role of cytokines and growth factors
The 2-AFF induced the proliferation of a periportal population of oval like cells ( Negative for expression of classical oval cell markers ) .However , the expression of these markers (AFP) started after two days ( Hepato-lineage ) affliated subpopulation .
Background & Aims: Although expandable hepatic progenitors
provide renewable cell sources for treatment of hepatic disorders,
long-term cultivation of hepatic progenitors may affect proliferation
and differentiation abilities, and even initiate the formation
of malignant cancer stem cells. This study aims to determine
characteristics of primary cultured hepatic oval cells after prolonged
cultivation in vitro.
This will be the steps this experiment.
1. The typical epithelial morphology of hepatic oval cells after serial passages. (A) The morphology of hepatic oval cells under low phase-contrast microscope
Fig. 2. Flow cytometry analysis demonstrating that hepatic oval cells expressed hepatic progenitor cell markers. The positive rate of the common marker for hepatic
oval cells, OV-6, at primary culture, 10th, 50th, and 100th passage, was 87.2%, 77.7%, 81.1%, and 76.7%, respectively. The expression of BD-1, BD-2, and Dlk, was over 85%,
90%, and 98%, respectively. As a negative control, primary cultured hepatocytes did not express these hepatic progenitor cell markers.
Fig. 3. Hepatic oval cells sustained expression of AFP, ALB, and CK19. (A) Immunofluorescence results showed that hepatic oval cells at the 0–2nd, 10th,
50th, and 100th passage expressed hepatocytic markers AFP and ALB. (B) Realtime RT-PCR results showed that hepatic oval cells had a sustained expression of
AFP, ALB, and CK19. (C) Western blot results demonstrated that in hepatic oval cells the expression of AFP, ALB, and CK19 persisted.
Fig. 4. Hepatocyte-specific differentiation capacity of hepatic oval cells after serial passages. (A) High power phase contrast images of hepatic oval cells exposed to
sodium butyrate (0.75 mM) for 3 days, and stained for Giemsa or PAS; hepatic oval cells at different passages increase in cell size, become binuclear and/or polyploid and
accumulate intracellular polysaccharides. Periodic acid–Schiff (PAS) is a staining method used to detect polysaccharides such as glycogen, and mucosubstances such as glycoproteins, glycolipids and mucins in tissues. (B) Western blot showing that the expression of ALB is upregulated, CK19 is slightly downregulated, while CK18 is significantly
decreased after sodium butyrate (0.75 mM) inducement from different passages of oval cells. (C and D) Quantification of the albumin secretion and ureagenesis showing
that albumin in the supernatant is increased and transformed urea is also increased at different passages of oval cells after sodium butyrate (0.75 mM) treatment.
B) Western blot showing that the expression of ALB is upregulated, CK19 is slightly downregulated, while CK18 is significantly
decreased after sodium butyrate (0.75 mM) inducement from different passages of oval cells. (C and D) Quantification of the albumin secretion and ureagenesis showing
that albumin in the supernatant is increased and transformed urea is also increased at different passages of oval cells after sodium butyrate (0.75 mM) treatment.
Fig. 5. Hepatic oval cells survive after serial passages without loss of their proliferation ability and maintain diploid cells with features of chromosomal
stability. (A) Growth curves for the cell count of hepatic oval cells revealed that their doubling time at the 0–2nd, 10th, 50th, and 100th passage was 25.8, 25.4,
22.3, and 23.1 h, respectively. (B) Representative flow cytometry analysis of DNA content and cell cycle showing that hepatic oval cells sustain their proliferation
potential and maintain the typical PI-staining pattern for diploid cells.
Fig. 6. Colony formation in vitro and tumorigenesis in vivo. (A) HepG2 cells and hepatic oval cells at different passages plated in soft agar for 3 weeks. Unlike the positive
control, tumorigenic HepG2 cells, hepatic oval cells at different passages fail to proliferate in soft agar. (B and C) Quantification by ELISPOT of the rate of formation of
colonies (B), and the % of the well area covered (C) (*p <0.05) for hepatic oval cells, there is no significant difference in colony number and covered area at the 0–2nd, 10th,
50th, and 100th passage. (D) In vivo tumorigenesis by injection of different passages of oval cells subcutaneously in the left flank of the immunodeficient mouse (five mice
per group); the positive control cells, HepG2, induce tumors after 2 and 4 weeks in the immunodeficient mice, while the oval cells cause no tumors.
Fig. 6. Colony formation in vitro and tumorigenesis in vivo. (A) HepG2 cells and hepatic oval cells at different passages plated in soft agar for 3 weeks. Unlike the positive
control, tumorigenic HepG2 cells, hepatic oval cells at different passages fail to proliferate in soft agar. (B and C) Quantification by ELISPOT of the rate of formation of
colonies (B), and the % of the well area covered (C) (*p <0.05) for hepatic oval cells, there is no significant difference in colony number and covered area at the 0–2nd, 10th,
50th, and 100th passage. (D) In vivo tumorigenesis by injection of different passages of oval cells subcutaneously in the left flank of the immunodeficient mouse (five mice
per group); the positive control cells, HepG2, induce tumors after 2 and 4 weeks in the immunodeficient mice, while the oval cells cause no tumors.